DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 11:13:51 05/07/2024 pm IST | ||
| 0.072 EUR | -18.18% |
|
| Current month | +28.57% | ||
| 1 month | -2.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 0.072 | -18.18% |
| 04/24/04 | 0.088 | -12.00% |
| 03/24/03 | 0.1 | +56.25% |
| 02/24/02 | 0.064 | +39.13% |
| 01/24/01 | 0.046 | -17.86% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 11:13 pm IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM37QP |
| ISIN | DE000VM37QP2 |
| Date issued | 19/10/2023 |
| Strike | 100 $ |
| Maturity | 20/12/2024 (168 Days) |
| Parity | 10 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.88 € |
|---|---|
| Lowest since issue | 0.046 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
